Hypo- vs. normofractionated radiation therapy in breast cancer: A patterns of care analysis in German speaking countries.
Breast cancer
DEGRO, German Society of Radiation Oncology
Gy, gray
HF-RT, hypofractionated radiotherapy
Hypofractionated radiotherapy
IORT, intraoperative radiation therapy
Normofractionated radiotherapy
Patterns of care
RT, radiation therapy
SIB, simultaneous integrated boost
SOP, standard operating procedure
Journal
Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
ISSN: 1507-1367
Titre abrégé: Rep Pract Oncol Radiother
Pays: Poland
ID NLM: 100885761
Informations de publication
Date de publication:
Historique:
received:
22
11
2019
revised:
31
05
2020
accepted:
24
07
2020
entrez:
9
9
2020
pubmed:
10
9
2020
medline:
10
9
2020
Statut:
ppublish
Résumé
To assess the use of hypofractionated (HG-RT) versus normofractionated radiation therapy (NF-RT) in Breast Cancer in German speaking countries. Between July 2017 and August 2017, an email-based survey was sent to all 1408 physicians that are members of the German Society of Radiation Oncology (DEGRO). The survey was completed by 180 physicians including 10 private practice owners and 52 heads of departments. The majority (82.1%) of the participants had >15 years of experience in radiation therapy (RT). The majority (83.9%) of the heads of the departments agreed on using the normofractionated regimen of RT as standard treatment for breast cancer. Several physicians were skeptical about HF-RT with 6.5% of the heads refusing to use HF-RT. 40.3% of the departments had not seen the new German guidelines suggesting HF-RT as the standard treatment for all patients as positive or merely adopted a neutral position toward the guidelines (33.9%). The main points of criticism were increased side effects, an impaired toxicity profile and insufficient data. Most departments (46.8%) that perform HF-RT do so in an individual based manner. HF-RT remains controversial in German speaking countries. Our data shows that NF-RT remains the predominant method of treatment. HF-RT is only used in a defined group of patients as most German physicians agree that particular patients, especially those at higher risk of RT late effects, may benefit from a less intense, extended fractionation schedule.
Sections du résumé
AIM AND BACKGROUND
OBJECTIVE
To assess the use of hypofractionated (HG-RT) versus normofractionated radiation therapy (NF-RT) in Breast Cancer in German speaking countries.
MATERIALS AND METHODS
METHODS
Between July 2017 and August 2017, an email-based survey was sent to all 1408 physicians that are members of the German Society of Radiation Oncology (DEGRO). The survey was completed by 180 physicians including 10 private practice owners and 52 heads of departments. The majority (82.1%) of the participants had >15 years of experience in radiation therapy (RT).
RESULTS
RESULTS
The majority (83.9%) of the heads of the departments agreed on using the normofractionated regimen of RT as standard treatment for breast cancer. Several physicians were skeptical about HF-RT with 6.5% of the heads refusing to use HF-RT. 40.3% of the departments had not seen the new German guidelines suggesting HF-RT as the standard treatment for all patients as positive or merely adopted a neutral position toward the guidelines (33.9%). The main points of criticism were increased side effects, an impaired toxicity profile and insufficient data. Most departments (46.8%) that perform HF-RT do so in an individual based manner.
CONCLUSIONS
CONCLUSIONS
HF-RT remains controversial in German speaking countries. Our data shows that NF-RT remains the predominant method of treatment. HF-RT is only used in a defined group of patients as most German physicians agree that particular patients, especially those at higher risk of RT late effects, may benefit from a less intense, extended fractionation schedule.
Identifiants
pubmed: 32904392
doi: 10.1016/j.rpor.2020.07.003
pii: S1507-1367(20)30103-6
pmc: PMC7453120
doi:
Types de publication
Journal Article
Langues
eng
Pagination
775-779Informations de copyright
© 2020 Published by Elsevier B.V. on behalf of Greater Poland Cancer Centre.
Références
Radiother Oncol. 1987 Apr;8(4):363-7
pubmed: 3589000
World J Radiol. 2010 Jun 28;2(6):197-202
pubmed: 21160631
Breast Care (Basel). 2009;4(2):75-80
pubmed: 20847883
Radiother Oncol. 2017 Apr;123(1):22-28
pubmed: 28236538
Cancers (Basel). 2015 May 22;7(2):908-29
pubmed: 26010605
Lancet. 2008 Mar 29;371(9618):1098-107
pubmed: 18355913
Radiat Oncol J. 2016 Jun;34(2):81-7
pubmed: 27306774
Breast. 2010 Jun;19(3):163-7
pubmed: 20511064
Breast Cancer. 2010;17(1):42-7
pubmed: 19350358
N Engl J Med. 1997 Oct 2;337(14):949-55
pubmed: 9395428
Lancet Oncol. 2010 Mar;11(3):231-40
pubmed: 20138809
Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2):266-272
pubmed: 27473814
Radiat Oncol. 2014 Apr 24;9:97
pubmed: 24762173
Lancet. 2020 May 23;395(10237):1613-1626
pubmed: 32580883
Clin Oncol (R Coll Radiol). 2007 Mar;19(2):120-4
pubmed: 17355107
N Engl J Med. 2010 Feb 11;362(6):513-20
pubmed: 20147717
Lancet Oncol. 2013 Oct;14(11):1086-1094
pubmed: 24055415
Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):154-62
pubmed: 15629606
Future Oncol. 2016 Apr;12(7):893-6
pubmed: 26880387
J Egypt Natl Canc Inst. 2004 Sep;16(3):178-87
pubmed: 15959551
J Natl Cancer Inst. 2002 Aug 7;94(15):1143-50
pubmed: 12165639
Lancet. 2014 Jun 21;383(9935):2127-35
pubmed: 24656685